| 2.89 0.08 (2.85%) | 06-15 09:40 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.02 | 1-year : | 4.7 |
| Resists | First : | 3.45 | Second : | 4.02 |
| Pivot price | 2.78  |
|||
| Supports | First : | 2.4 | Second : | 1.75 |
| MAs | MA(5) : | 2.75  |
MA(20) : | 2.59 |
| MA(100) : | 2.01 |
MA(250) : | 1.46 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 52.7 |
D(3) : | 54.6 |
| RSI | RSI(14): 56.7 | |||
| 52-week | High : | 3.45 | Low : | 0.27 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EQ ] has closed below upper band by 47.6%. Bollinger Bands are 52.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.97 - 2.98 | 2.98 - 3 |
| Low: | 2.66 - 2.68 | 2.68 - 2.7 |
| Close: | 2.78 - 2.81 | 2.81 - 2.84 |
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Wed, 10 Jun 2026
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504 - Yahoo Finance
Fri, 05 Jun 2026
Insider Sell: Stephen Connelly Sells 230,975 Shares of Equillium Inc (EQ) - GuruFocus
Fri, 05 Jun 2026
Equillium (EQ) COO sells 14,584 shares after exercising stock options - Stock Titan
Fri, 05 Jun 2026
Equillium (NASDAQ: EQ) CSO Stephen Connelly sells 230,975 shares in open market - Stock Titan
Thu, 04 Jun 2026
[144] Equillium, Inc. SEC Filing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 16 (%) |
| Held by Institutions | 64.2 (%) |
| Shares Short | 3,610 (K) |
| Shares Short P.Month | 2,810 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.93 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32 % |
| Return on Equity (ttm) | -54.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -13.39 |
| PEG Ratio | 0 |
| Price to Book value | 2.98 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|